News

Oct 20, 2021
PHARMAMeiji Seika Pharma Announces the Launch of Hiyasta® Tablets 10mg, an Anti-Malignant Tumor Agent
Oct 15, 2021
HDIntegrated Report 2021
Oct 1, 2021
HDNotice that the Meiji Group has Adopted Internal Carbon Pricing
Sep 16, 2021
HDMeiji Group Joins a Global Initiative RE100
Sep 10, 2021
HDNotice concerning Recording Extraordinary Profit and Revisions to Financial Forecasts for the Fiscal Year Ending March 31, 2022
Sep 10, 2021
HDNotice regarding Company Split (Absorption-Type Company Split) and Transfer of Agricultural Chemicals Manufacturing and Sales Business (Change of Second-Generation Subsidiary)
Aug 24, 2021
PHARMAMeiji completed Phase I studies and moves onto Phase II study of ME3183, a selective PDE4 inhibitor for the treatment of psoriasis
Aug 12, 2021
HDConsolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022
Aug 12, 2021
HD[Presentation] Financial Results for the First Quarter of Fiscal Year Ending March 31, 2022
Aug 11, 2021
HDNotice Concerning Completion of Payment in Full for Disposal of Treasury Stock for Restricted Stock Compensation
July 21, 2021
PHARMAMeiji and Dong-A ST Enter into an Exclusive License Agreement with Intas to Commercialize DMB-3115, a Proposed Biosimilar to Ustekinumab
July 16, 2021
HDNotice concerning the Disposal of Treasury Stock for Restricted Stock Compensation
July 7, 2021
HDWe updated ESG Data
June 24, 2021
PHARMAMarketing Approval of HBI-8000 (Tucidinostat) for Relapsed or Refractory ATLL Treatment in Japan
June 16, 2021
HD[Presentation] IR Day
June 9, 2021
HDApproach and Policy Concerning Lowering of Trading Unit
June 4, 2021
HDNotice of the 12th Ordinary General Meeting of Shareholders
May 26, 2021
HD[Presentation] Financial Results for the Fiscal Year Ended March 31, 2021
May 21, 2021
PHARMAPromising results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients with Plaque Psoriasis
May 18, 2021
HD【Presentation】Financial Results for the Fiscal Year Ended March 31, 2021
May 18, 2021
HDNotice concerning surplus dividends
May 18, 2021
HDConsolidated Financial Results for the Fiscal Year Ended March 31, 2021
May 18, 2021
HDMeiji Group Slogan to Be Updated: Now ideas for wellness
May 18, 2021
HDNotice Concerning Postponement of Announcement of Financial Results for the Fiscal Year Ended March 31, 2021
May 17, 2021
HDNotice Concerning the Scheduled Date of Announcement of Financial Results for the Fiscal Year Ended March 31, 2021
May 13, 2021
PHARMAMEIJI AND UPL ENTER INTO LICENSEING AGREEMENT CONCERNING NEW INSECTICIDE FLUPYRIMIN IN SOUTHEAST ASIA
May 12, 2021
HDNotice Concerning Postponement of Announcement of Financial Results
Apr 16, 2021
HDNotice concerning Decision of Issuance Conditions for Sustainability Bonds
Apr 09, 2021
HDNotice concerning Investment in New Protein Fund Formed by US Venture Capital Fund, Big Idea Ventures
Apr 07, 2021
PHARMAApplication for Additional Indication of HBI-8000 Submitted for Relapsed or Refractory PTCL Treatment
Mar 26, 2021
FOODNotice concerning launch of probiotic yogurts, "Meiji Probio Yogurt R-1" and "Meiji Probio Yogurt LG21" in China
Mar 25, 2021
PHARMAKM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)
Mar 17, 2021
FOODThe first ever in Europe, Danone branded formula milk in tablet format launched in the UK 〜 Business partnership with Danone to produce infant formula tablets 〜
Mar 17, 2021
HD【Presentation】 〜Long-term Environmental Vision, Meiji Green Engagement For 2050〜
Mar 15, 2021
HDNotice concerning Issuance of Sustainability Bonds
Mar 12, 2021
FOODMeiji Establishes New Company in Vietnam 〜 Aiming for the further expansion of its infant formula business in Vietnam 〜
Mar 1, 2021
HDMeiji Group Outlines Long-term Environmental Vision, the Meiji Green Engagement For 2050
Feb 19, 2021
HDMeiji Group Social Contribution Activities Policy has been published.
Feb 9, 2021
HD【Presentation】Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2021
Feb 9, 2021
HDConsolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2021
Feb 9, 2021
HDNotice Concerning Revisions to Financial Forecasts for the Fiscal Year Ending March 31, 2021
Jan 15, 2021
HDNotice Concerning the Creation of Sustainability Finance Framework
Jan 8, 2021
PHARMAMeiji Seika Pharma Initiates Phase 1 Trial of ME3208 in Japan for cGVHD
Jan 5, 2021
PHARMAMeiji Seika Pharma sets up a new subsidiary in the US